Abstract 152P
Background
Neoadjuvant chemoradiotherapy (nCRT) is the standard initial treatment for locally advanced rectal cancer (LARC) to reduce tumor size before surgery. Although some patients achieve complete pathological response and become eligible for organ-preserving strategies, predicting nCRT response remains challenging. The intratumoral genetic heterogeneity (ITGH) has emerged as a potential biomarker in LARC patients. Tumor-infiltrating lymphocytes (TILs) enriched with cytotoxic CD8+ T-cells indicate better prognosis and treatment response. An immunohistochemistry-based score, estimating CD3+ and CD8+ enrichment in LARC TILs, is proposed as a predictive test. Elements from anti-tumoral immune response could serve as potential predictive biomarkers.
Methods
We analyzed 80 primary LARC tumors (18 responders, nCRT-R, versus nonresponders 62, nCRT-NR) through WXS and TCRseq. We evaluated nCRT response, tumor mutation burden (TMB), neoantigen load (NAL), HLA polymorphism, somatic mutation, TCR diversity/clonality, ITGH levels, and DNA mismatch repair deficiency.
Results
We identified six significantly mutated genes (KRAS, APC, TP53, FBXW7, ARID1A, SLITRK6) (p<0.05; FDR<=0.1). Somatic mutations in driver genes, 23 dMMR genes, and COSMIC somatic signatures S6, S15, S20, or S26 did not show any association with nCRT response (p>0.5; Fisher Test). We measured ITGH through MATH score, but no significant difference between nCRT-R and NR (p=0.8; Wilcoxon test) was observed. TMB and NAL were significantly higher in nCRT-NR (p<0.05). HLA somatic mutation did not have a significant impact on antigen presentation and treatment response (8 mutations in 8 patients; Pearson Chi-squared, p=0.76). HLA polymorphism was not relevant (Pearson Chi-squared, p=0.64). Finally, nCRT response was not associated with TCR Shannon diversity or clonality (Wilcoxon test, p=0.25 and p=0.48, respectively); however, we could not quantify CD8+ T-cells.
Conclusions
Gene driver signature, ITGH, or dMMR mutations/signatures were not predictive biomarkers of nCRT response; however, preliminary findings suggest a subset of highly immunogenic nCRT-NR LARCs patients could benefit from immunotherapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
R. Perez.
Funding
FAPESP: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract